Schizophrenia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$14995
Buy Report

Published: December 06, 2024 Report Code: GDHC304PIDR-7M-ST

Select Item

Schizophrenia Market Report Overview

The schizophrenia market size across the 7MM was $8.4 billion in 2021 and will achieve a CAGR of more than 7% during 2021-2031. The market growth is attributed to the launch of 11 new pipeline products, all of which will have higher ACOTs compared with the cost of the most commonly used antipsychotic treatments, which are highly genericized.

Schizophrenia Market Outlook, 2021-2031 ($ Billion)

Schizophrenia Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report for More Insights on the Schizophrenia Market Report Forecast

Download a Free Report Sample

The schizophrenia market research report provides a granular forecast growth analysis for both global and regional markets through 2030. The report also provides an in-depth assessment of the respiratory syncytial virus prophylaxis market including disease overview, epidemiology, and disease management. Furthermore, the report delves into current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook. Additionally, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.

Market Size (2021) $8.4 Billion
CAGR (2021-2031) >7%
Forecast Period 2021-2031
Key Countries ·       The US

·       France

·       Germany

·       Italy

·       Spain
Leading Players ·       Medincell

·       Lilly

·       Johnson & Johnson

·       Eli Lilly

·       Otsuka
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Schizophrenia Market Segmentation by Countries

The key countries encompassing the schizophrenia market include the US, France, Germany, Italy, Spain, and others. In 2021, the US accounted for the highest country share of the schizophrenia market across the 7MM.

Schizophrenia Market Analysis by Countries, 2021 (%)

Schizophrenia Market Analysis by Countries, 2021 (%)

Buy the Full Report for More Regional Insights on the Schizophrenia Market
Download a Free Report Sample

Schizophrenia Market – Competitive Landscape

A few of the major players in the schizophrenia market are:

  • Medincell
  • Lilly
  • Johnson & Johnson
  • Eli Lilly
  • Otsukaothers

Historically, Johnson & Johnson, Eli Lilly, and Otsuka have held dominant shares of the schizophrenia market. Flagship brands from these companies include Johnson & Johnson’s Risperdal and Invega, Eli Lilly’s Zyprexa, and Otsuka’s Abilify. These companies have utilized similar lifecycle management strategies to prolong their products’ revenues. Furthermore, new players are entering the schizophrenia market throughout the forecast period, including Boehringer Ingelheim, Newron Pharmaceuticals, Neurocrine Biosciences, Lyndra Therapeutics, and Reviva Pharmaceuticals. These companies do not currently market any products for schizophrenia but will find their niches in this competitive market.

Schizophrenia Market by Players

Schizophrenia Market by Players

Buy the Full Report for More Player Insights on the Schizophrenia Market
Download a Free Report Sample

Segments Covered in the Report

Schizophrenia Market Country Outlook (Value, $ Billion, 2021-2031)

  • The US
  • France
  • Germany
  • Italy
  • Spain

Scope

  • Overview of Schizophrenia, including epidemiology, symptoms, diagnosis, and disease management.

  • Annualized schizophrenia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the schizophrenia therapeutics market.

  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for schizophrenia treatment. The most promising candidates in late-stage development are profiled.

  • Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the 7MM schizophrenia therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM schizophrenia therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments,s and strategic partnerships.

Alexza Pharmaceuticals
Alkermes Plc
Astellas
AstraZeneca
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol Myers Squibb
Eli Lilly
Gedeon Richter
Hisamitsu Pharmaceuticals
Indivior
Intra-Cellular Therapies Inc
Johnson & Johnson
Laboratorios Farmaceuticos Rovi
Lundbeck
Luye Pharma Group
Lyndra Therapeutics Inc.
MedinCell
Merck & Co
Neurocrine Biosciences Inc
Newron Pharmaceuticals SpA
Otsuka Pharmaceutical Co Ltd
Reviva Pharmaceuticals Inc
Sumitomo Dainippon
Sumitomo Pharma Co Ltd
Teva Pharmaceutical Industries Ltd
Vanda Pharmaceuticals Inc

Table of Contents

About GlobalData

List of Contents

List of Tables

List of Figures

1 Schizophrenia: Executive Summary – Updated November 2024, Based on Events up to November 22

1.1 The schizophrenia market will grow to $17.0 billion.

1.2 Key players will struggle to maintain their competitive position.

1.3 While outlook for schizophrenia management made headway, opportunities remain to improve patient outcomes.

1.4 The entry of adjunctive therapies will shape the schizophrenia market.

1.5 What do physicians think?

2 Introduction – Updated November 2024

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities.

4.3 Global and historical trends

4.4 7MM forecast methodology.

4.4.1 Sources used.

4.4.2 Forecast assumptions and methods.

4.4.3 Forecast assumptions and methods: 12-month total prevalent cases of schizophrenia.

4.5 Epidemiological Forecast for Schizophrenia (2021–31)

4.5.1 12-Month total prevalent cases of schizophrenia

4.5.2 12-Month diagnosed prevalent cases of schizophrenia

4.5.3 Age-specific 12-month diagnosed prevalent cases of schizophrenia.

4.5.4 Sex-specific 12-month diagnosed prevalent cases of schizophrenia.

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management – Updated November 2024, Based on Events up to November 22

5.1 Diagnosis overview

5.2 Treatment overview

5.3 Non-pharmacological management of schizophrenia

6 Competitive Assessment – Updated November 2024, Based on Events up to November 22

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated November 2024, Based on Events up to November 22

7.1 Overview

7.2 Development of therapies to target cognitive impairment associated with schizophrenia

7.3 Development of therapies to target negative symptoms.

7.4 Development of therapies for treatment-resistant patients

7.5 Improved patient insight and adherence to treatment

8 R&D Strategies – Updated November 2024, Based on Events up to November 22

8.1 Overview

8.1.1 Reformulations and innovative drug delivery systems

8.1.2 Novel MOAs

8.1.3 Development of adjunctive therapies

8.1.4 Digital therapeutics

8.2 Clinical trial design

8.2.1 Clinical endpoints

8.2.2 Patient Recruitment

9 Pipeline Assessment – Updated November 2024, Based on Events up to November 22

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis – Updated November 2024, Based on Events up to November 22

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players – Updated November 2024, Based on Events up to November 22

11.1 Overview

11.2 Deal-making trends

12 Market Outlook – Updated November 2024, Based on Events up to November 22

12.1 Global Markets

12.1.1 Forecasts

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs and Payers

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologists

13.6.5 Vice President of Disease Analysis and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence

Contact Us

Table

Table 1: Schizophrenia: Key metrics in the 7MM

Table 2: Risk factors and comorbid conditions associated with schizophrenia

Table 3: Treatment Guidelines for Schizophrenia

Table 4: Schizophrenia market – global drivers and barriers, 2021–31

Table 5: Key events impacting sales for schizophrenia in the US, 2021–31

Table 6: Schizophrenia Market – Drivers and Barriers in the US, 2021–31

Table 7: Key events impacting sales for schizophrenia in the 5EU, 2021–31

Table 8: Schizophrenia market – drivers and barriers in the 5EU, 2021–31

Table 9: Key Events Impacting Sales for Schizophrenia in Japan, 2021–31

Table 10: Schizophrenia Market – Drivers and Barriers in Japan, 2021–31

Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global sales forecast by country for schizophrenia in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in schizophrenia during the forecast period

Figure 3: Competitive assessment of oral pipeline products that GlobalData expects to be licensed for the treatment of schizophrenia during the forecast period

Figure 4: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna

Figure 5: 7MM, 12-month total prevalence (%) of schizophrenia, both sexes, ages ≥13 years, 2021

Figure 6: 7MM, 12-month diagnosed prevalence (%) of schizophrenia, men and women, ages ≥13 years, 2021

Figure 7: 7MM, sources used to forecast the 12-month total prevalent cases of schizophrenia

Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of schizophrenia

Figure 9: 7MM, 12-month total prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021

Figure 10: 7MM, 12-month diagnosed prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021

Figure 11: 7MM, 12-month diagnosed prevalent cases of schizophrenia by age, N, both sexes, 2021

Figure 12: 7MM, 12-month diagnosed prevalent cases of schizophrenia by sex, N, ages ≥13 years, 2021

Figure 13: Unmet needs and opportunities in schizophrenia

Figure 14: Overview of the development pipeline in schizophrenia

Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects to be launched for schizophrenia in the 7MM during the forecast period

Figure 16: Competitive assessment of oral pipeline drugs benchmarked against the SOC, Abilify

Figure 17: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna

Figure 18: Analysis of the company portfolio gap in schizophrenia during the forecast period

Figure 19: Global (7MM) sales forecast by country for schizophrenia in 2021 and 2031

Figure 20: Sales forecast by class for schizophrenia in the 7MM in 2021 and 2031

Figure 21: Sales forecast by class for schizophrenia in the US in 2021 and 2031

Figure 22: Sales forecast by class for schizophrenia in the 5EU in 2021 and 2031

Figure 23: Sales forecast by class for schizophrenia in Japan in 2021 and 2031

Frequently asked questions

Schizophrenia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031 standard reports
Currency USD
$14,995

Can be used by individual purchaser only

Most Popular
$29,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$44,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Schizophrenia reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Schizophrenia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031 in real time.

  • Access a live Schizophrenia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more